Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function

Journal of Immunology

Volumn 184, Issue 9, 2010, Pages 4936-4946

  Schmid, Daphné A ^a   Irving, Melita B ^a   Posevitz, Vilmos ^a   Hebeisen, Michael ^b   Posevitz Fejfar, Anita ^b   Sarria, J C Floyd ^c   Gomez Eerland, Raquel ^e   Thome, Margot ^b   Schumacher, Ton N M ^e   Romero, Pedro ^a   Speiser, Daniel E ^a   Zoete, Vincent ^d   Michielin, Olivier ^a,d   Rufer, Nathalie ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c EPFL   (Switzerland)

^d SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; CTAG1B PROTEIN, HUMAN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PEPTIDE NY ESO 1 157 165; PEPTIDE NY-ESO-1 157-165; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; CYTOLYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR AFFINITY; CELL ADHESION; CELL CULTURE; CELL LINE; CYTOTOXICITY; GENETICS; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HLA-A ANTIGENS; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA;

EID: 77954472387     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000173     Document Type: Article

References (53)

1. Speiser, D. E., D. Kyburz, U. Stübi, H. Hengartner, and R. M. Zinkernagel. 1992. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149: 972-980.
2. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 93: 4102-4107.
3. Gallimore, A., T. Dumrese, H. Hengartner, R. M. Zinkernagel, and H.G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187: 1647-1657.
4. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
5. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
6. Davis, M. M., J. J. Boniface, Z. Reich, D. Lyons, J. Hampl, B. Arden, and Y. Chien. 1998. Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol. 16: 523-544.
7. Savage, P. A., and M. M. Davis. 2001. A kinetic window constricts the T cell receptor repertoire in the thymus. Immunity 14: 243-252.
8. Stone, J. D., A. S. Chervin, and D. M. Kranz. 2009. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126: 165-176.
9. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227-2234. (Pubitemid 29288845)
10. Zeh, H. J., 3rd, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162: 989-994.
11. Dudley, M. E., M. I. Nishimura, A. K. Holt, and S. A. Rosenberg. 1999. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J. Immunother. 22: 288-298.
12. Dutoit,V.,V.Rubio-Godoy, P.Y. Dietrich,A.L.Quiqueres,V. Schnuriger,D.Rimoldi, D. Liénard, D. Speiser, P. Guillaume, P. Batard, et al. 2001. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 61: 5850-5856.
13. Gilboa, E. 1999. The makings of a tumor rejection antigen. Immunity 11: 263-270.
14. Rosenberg, S. A., M. E. Dudley, and N. P. Restifo. 2008. Cancer immunotherapy. N. Engl. J. Med. 359: 1072.
15. Dutoit, V., V. Rubio-Godoy, M. A. Doucey, P. Batard, D. Liénard, D. Rimoldi, D. Speiser, P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2002. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 168: 1167-1171.
16. Dutoit, V., P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2002. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. Eur. J. Immunol. 32: 3285-3293.
17. Malherbe, L., C. Hausl, L. Teyton, and M. G. McHeyzer-Williams. 2004. Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. Immunity 21: 669-679. (Pubitemid 39487890)
18. Snyder, J. T., M. A. Alexander-Miller, J. A. Berzofskyl, and I. M. Belyakov. 2003. Molecular mechanisms and biological significance of CTL avidity. Curr. HIV Res. 1: 287-294.
19. Barbey, C., P. Baumgaertner, E. Devevre, V. Rubio-Godoy, L. Derre, G. Bricard, P. Guillaume, I. F. Luescher, D. Liénard, J. C. Cerottini, et al. 2007. IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J. Immunol. 178: 3566-3574.
20. Li, Y., R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, and J. M. Boulter. 2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23: 349-354.
21. Dunn, S. M., P. J. Rizkallah, E. Baston, T. Mahon, B. Cameron, R. Moysey, F. Gao, M. Sami, J. Boulter, Y. Li, and B. K. Jakobsen. 2006. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci. 15: 710-721.
22. Holler, P. D., A. R. Lim, B. K. Cho, L. A. Rund, and D. M. Kranz. 2001. CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J. Exp. Med. 194: 1043-1052.
23. Chlewicki, L. K., P. D. Holler, B. C. Monti, M. R. Clutter, and D. M. Kranz. 2005. High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J. Mol. Biol. 346: 223-239.
24. Zhao, Y., A. D. Bennett, Z. Zheng, Q. J. Wang, P. F. Robbins, L. Y. Yu, Y. Li, P. E. Molloy, S. M. Dunn, B. K. Jakobsen, et al. 2007. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 179: 5845-5854.
25. Robbins, P. F., Y. F. Li, M. El-Gamil, Y. Zhao, J. A. Wargo, Z. Zheng, H. Xu, R. A. Morgan, S. A. Feldman, L. A. Johnson, et al. 2008. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180: 6116-6131.
26. Varela-Rohena, A., P. E.Molloy, S.M. Dunn, Y. Li,M.M. Suhoski, R. G. Carroll, A. Milicic, T. Mahon, D. H. Sutton, B. Laugel, et al. 2008. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 14: 1390-1395.
27. Holler, P. D., L. K. Chlewicki, and D. M. Kranz. 2003. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4: 55-62.
28. Zoete, V., and O. Michielin. 2007. Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex. Proteins 67: 1026-1047. (Pubitemid 46753949)
29. Zoete, V., M. B. Irving, and O. Michielin. 2010. MM-GBSA binding free energy decomposition and T cell receptor engineering. J. Mol. Recognit. 23: 142-152.
30. Arden, B., S. P. Clark, D. Kabelitz, and T. W. Mak. 1995. Human T-cell receptor variable gene segment families. Immunogenetics 42: 455-500. (Pubitemid 26025063)
31. Derré, L., M. Bruyninx, P. Baumgaertner, M. Ferber, D. Schmid, A. Leimgruber, V. Zoete, P. Romero, O. Michielin, D. E. Speiser, and N. Rufer. 2008. Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc. Natl. Acad. Sci. U.S.A. 105: 15010-15015.
32. Dull, T., R. Zufferey,M.Kelly, R. J.Mandel, M. Nguyen, D. Trono, and L. Naldini. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72: 8463-8471. (Pubitemid 28471781)
33. Derré, L., M. Bruyninx, P. Baumgaertner, E. Devevre, P. Corthesy, C. Touvrey, Y. D. Mahnke, H. Pircher, V. Voelter, P. Romero, et al. 2007. In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. J. Immunol. 179: 2368-2379.
34. Romero, P., V. Dutoit, V. Rubio-Godoy, D. Liénard, D. Speiser, P. Guillaume, K. Servis, D. Rimoldi, J. C. Cerottini, and D. Valmori. 2001. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin. Cancer Res. 7(3 Suppl)766s-772s.
35. Le Gal, F. A., M. Ayyoub, V. Dutoit, V. Widmer, E. Jäger, J. C. Cerottini, P. Y. Dietrich, and D. Valmori. 2005. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumorspecific antigen NY-ESO-1. J. Immunother. 28: 252-257.
36. Chen, J. L., G. Stewart-Jones, G. Bossi, N. M. Lissin, L. Wooldridge, E. M. Choi, G.Held, P.R.Dunbar,R. M.Esnouf,M. Sami, et al. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201: 1243-1255.
37. Smith, S. D., R. Morgan, R. Gemmell, M. D. Amylon, M. P. Link, C. Linker, B. K. Hecht, R. Warnke, B. E. Glader, and F. Hecht. 1988. Clinical and biologic characterization of T-cell neoplasias with rearrangements of chromosome 7 band q34. Blood 71: 395-402.
38. Boniface, J. J., J. D. Rabinowitz, C. Wülfing, J. Hampl, Z. Reich, J. D. Altman, R. M. Kantor, C. Beeson, H. M. McConnell, and M. M. Davis. 1998. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. [Published erratum appears in 1998 Immunity. 9: 891.] Immunity 9: 459-466.
39. Minguet, S., M. Swamy, B. Alarcón, I. F. Luescher, and W. W. Schamel. 2007. Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity 26: 43-54. (Pubitemid 46109342)
40. Berg, N. N., L. G. Puente, W. Dawicki, and H. L. Ostergaard. 1998. Sustained TCR signaling is required for mitogen-activated protein kinase activation and degranulation by cytotoxic T lymphocytes. J. Immunol. 161: 2919-2924. (Pubitemid 28425714)
41. Ohnishi, H., K. Takeda, J. Domenico, J. J. Lucas, N. Miyahara, C. H. Swasey, A. Dakhama, and E. W. Gelfand. 2009. Mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-dependent pathways are essential for CD8+ T cell-mediated airway hyperresponsiveness and inflammation. J. Allergy Clin. Immunol. 123: 249-257.
42. Pittet, M. J., V. Rubio-Godoy, G. Bioley, P. Guillaume, P. Batard, D. Speiser, I. Luescher, J. C. Cerottini, P. Romero, and A. Zippelius. 2003. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J. Immunol. 171: 1844-1849.
43. Bendle, G. M., J. B. Haanen, and T. N. Schumacher. 2009. Preclinical development of T cell receptor gene therapy. Curr. Opin. Immunol. 21: 209-214.
44. Rosenberg, S. A., and M. E. Dudley. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21: 233-240.
45. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
46. Johnson, L. A., R. A.Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
47. Offringa, R. 2009. Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 21: 190-199.
48. Krogsgaard, M., and M. M. Davis. 2005. How T cells 'see' antigen. Nat. Immunol. 6: 239-245.
49. McKeithan, T. W. 1995. Kinetic proofreading in T-cell receptor signal transduction. Proc. Natl. Acad. Sci. U.S.A. 92: 5042-5046.
50. Rabinowitz, J. D., C. Beeson, D. S. Lyons, M. M. Davis, and H. M. McConnell. 1996. Kinetic discrimination in T-cell activation. Proc. Natl. Acad. Sci. U.S.A. 93: 1401-1405.
51. Valitutti, S., S. Müller, M. Cella, E. Padovan, and A. Lanzavecchia. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375: 148-151.
52. Kalergis, A. M., N. Boucheron, M. A. Doucey, E. Palmieri, E. C. Goyarts, Z. Vegh, I. F. Luescher, and S. G. Nathenson. 2001. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2: 229-234.
53. Chervin, A. S., J. D. Stone, P. D. Holler, A. Bai, J. Chen, H. N. Eisen, and D. M. Kranz. 2009. The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J. Immunol. 183: 1166-1178.